Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) Journal of Pharmaceutical and Sciences.
Didik Hasmono
University of Muhammadiyah Malang
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Studi Pemberian Diuretik Pada Pasien Sirosis Hepatik Dengan Komplikasi Asites di RSUD dr. Iskak Tulungagung. Agies Annastasya P.D.; Alvina Arum Puspitasari; Didik Hasmono; Binti Muzayyanah
Journal of Pharmaceutical and Sciences JPS Volume 9 Nomor 1 (2026)
Publisher : Fakultas Farmasi Universitas Tjut Nyak Dhien

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36490/journal-jps.com.v9i1.741

Abstract

According to the World Health Organization (WHO), cirrhosis is a structural change of the liver from normal to abnormal, characterized by fibrosis. Ascites is the most common complication in liver cirrhosis patients with the primary trigger (75%) is portal hypertension. The treatment focuses on removing the fluid from the peritoneal cavity. This study aim to understanding the pattern of diuretic use as ascites therapy in patients with cirrhosis hepatic. An observational study with a retrospective and descriptive approach using total sampling method in patients diagnosed with cirrhosis and ascites who received diuretics at Dr Iskak Tulungagung general hospital during January-December 2022 were conducted. The tools used in this study include medical records, data collection sheets, clinical data sheets, and laboratory data. Among 62 patients, 16 (26%) received spironolactone monotherapy, 9 (14%) furosemide monotherapy, 21 (34%) combination therapy, and 16 (26%) underwent switching between regimens. Spironolactone, particularly at 100 mg orally once daily, either alone or in combination with furosemide (40 mg intravenously once daily), was the most frequently prescribed diuretic regimen. These findings indicate that the therapeutic approach applied in clinical practice has generally followed the AASLD guideline recommendations.
Profile of Erythropoietin Use and Hemoglobin Levels in Chronic Kidney Disease Patients with Anemia Undergoing Hemodialysis Irsan Fahmi Almuhtarihan; Triana Emilya Rosa; Nailis Syifa; Aghnia Fuadatul Inayah; Didik Hasmono
PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) Jurnal Pharmacy, Vol. 23 No. 01 Juli 2026
Publisher : Pharmacy Faculty, Universitas Muhammadiyah Purwokerto

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30595/pharmacy.v23i1.28486

Abstract

Anemia is a common complication of chronic kidney disease (CKD) caused by decreased endogenous erythropoietin production. Exogenous erythropoietin is administered to increase hemoglobin levels; however, patient responses may vary. This research aimed to identify patterns of erythropoietin use and describe hemoglobin levels before and after hemodialysis in CKD patients with anemia. This retrospective observational study used a cross-sectional design and medical record data from CKD patients with anemia who underwent hemodialysis and received erythropoietin from January to December 2023 at R.T. Notopuro Regional General Hospital, Sidoarjo. Hemoglobin change was calculated as post-hemodialysis hemoglobin minus pre-hemodialysis hemoglobin within the same session. Hemoglobin levels before and after dialysis were analyzed using a paired t-test. The dosage profile was presented descriptively. We analyzed 40 patients: 23 males (58%), 17 females (42%), and 35 patients (86%) aged >44 years. All patients received erythropoietin: 37 patients (92.5%) received 2000 IU, and 3 patients (7.5%) received 3000 IU. The mean hemoglobin level increased from 8.70 ± 1.01 g/dL before hemodialysis to 8.93 ± 1.10 g/dL after hemodialysis, with a mean change of +0.23 ± 0.80 g/dL (p=0.075). Based on dosage, the hemoglobin change was +0.21 ± 0.82 g/dL in the 2000 IU group and +0.53 ± 0.40 g/dL in the 3000 IU group. The erythropoietin use profile was dominated by erythropoietin alpha at a dose of 2000 IU. Hemoglobin levels after one hemodialysis session showed a small and statistically insignificant increase.
Co-Authors Aghnia Fuadatul Inayah Agies Annastasya P.D. Alvina Arum Puspitasari Binti Muzayyanah Irsan Fahmi Almuhtarihan Nailis Syifa Triana Emilya Rosa